Journal article
Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma
Abstract
IMPORTANCE: NRAS and BRAF mutations in melanoma inform current treatment paradigms, but their role in survival from primary melanoma has not been established. Identification of patients at high risk of melanoma-related death based on their primary melanoma characteristics before evidence of recurrence could inform recommendations for patient follow-up and eligibility for adjuvant trials.
OBJECTIVE: To determine tumor characteristics and …
Authors
Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L
Journal
JAMA Oncology, Vol. 1, No. 3, pp. 359–368
Publisher
American Medical Association (AMA)
Publication Date
June 1, 2015
DOI
10.1001/jamaoncol.2015.0493
ISSN
2374-2437
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAgedAged, 80 and overBiomarkers, TumorDNA Mutational AnalysisFemaleGTP PhosphohydrolasesGene FrequencyGenetic Predisposition to DiseaseHumansKaplan-Meier EstimateLymphocytes, Tumor-InfiltratingMaleMelanomaMembrane ProteinsMiddle AgedMultivariate AnalysisMutationNeoplasm GradingNeoplasm StagingNew South WalesOdds RatioPhenotypeProportional Hazards ModelsProto-Oncogene Proteins B-rafRisk AssessmentRisk FactorsSkin NeoplasmsTime FactorsTumor MicroenvironmentUnited States